Generic Medicine Info
Should be taken with food. Best taken w/ meals & a full glass of water.
Hypersensitivity to mefloquine and related compounds (e.g. quinidine, quinine). Prophylactic use in patients with psychosis, generalised anxiety disorder, suicidal ideations, behaviour, or attempts, active and recent history of depression, history of convulsions of any origin, schizophrenia, or other major psychiatric disorders; history of Blackwater fever. Concomitant use with halofantrine or within 15 weeks after the last dose of mefloquine.
Special Precautions
Patient with significant cardiac disease; previous history of depression; history of convulsions (if used as treatment). In cases of life-threatening, serious, or overwhelming P. falciparum malarial infections, patients should be treated with IV antimalarial drugs and mefloquine may be given orally to complete the course. Renal and hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, and vertigo, if affected, do not drive or operate machinery. Monitoring Parameters Monitor LFTs, evaluate neuropsychiatric effects, and perform eye examinations periodically if to be administered for a prolonged period. Monitor blood concentration of anti-seizure medicines if used concomitantly with mefloquine.
Adverse Reactions
Significant: Neuropsychiatric effects (e.g. attempted suicide, suicidal thoughts and behaviour, anxiety disorders, depression, bipolar disorder, paranoia, hallucinations, mood swings, panic attacks, psychotic and paranoid reactions, insomnia, abnormal dreams or nightmares, restlessness, confusion, dizziness, vertigo, loss of balance); hypersensitivity reactions; altered cardiac conduction (e.g. ECG alterations, 1st-degree atrioventricular block, sinus bradycardia, sinus arrhythmia, QTc interval prolongation, abnormal T waves); increase risk of convulsions in patients with epilepsy; polyneuropathy; ocular effects (e.g. retinal disorders, optic neuropathy); pneumonitis of possible allergic aetiology; agranulocytosis, aplastic anaemia; hypoglycaemia (particularly in patients with congenital hyperinsulinaemic hypoglycaemia). Blood and lymphatic system disorders: Leucopenia, leucocytosis, thrombocytopenia. Cardiac disorders: Extrasystoles. Ear and labyrinth disorders: Vestibular disorders, tinnitus, impaired hearing, hyperacusis, partial deafness (sometimes prolonged). Eye disorders: Visual impairment, blurred vision, cataract. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, pancreatitis. General disorders and administration site conditions: Asthenia, malaise, fatigue, pyrexia, chills, chest pain, oedema. Hepatobiliary disorders: Hepatitis, jaundice, hepatic failure. Investigations: Transient increased in ALT, AST, gamma-glutamyl transferase (GGT); increased blood creatinine, decreased haematocrit. Metabolism and nutrition disorders: Decreased appetite. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia, muscle weakness and spasms. Nervous system disorders: Cranial nerve paralysis, amnesia, somnolence, speech disorder, memory impairment, gait disturbance, balance disorder, peripheral sensory and motor neuropathy including paraesthesia, tremor, and ataxia. Renal and urinary disorders: Nephritis, acute renal failure. Respiratory, thoracic and mediastinal disorders: Pneumonia, dyspnoea. Skin and subcutaneous tissue disorders: Pruritus, Stevens-Johnson syndrome, rash, erythema multiforme, urticaria, hyperhidrosis, alopecia. Vascular disorders: Hypotension, hypertension, flushing, syncope.
Drug Interactions
Increased plasma concentration and elimination half-life with ketoconazole. May cause ECG abnormalities and increase the risk of convulsions with other related compounds (e.g. chloroquine, quinine, quinidine). May diminish the therapeutic effect by lowering the plasma concentrations of anticonvulsants (e.g. carbamazepine, valproic acid, phenytoin, phenobarbital). May increase the risk of convulsions with TCAs, SSRIs, bupropion, tramadol, antipsychotics, or some antibiotics. Decreased plasma concentration with CYP3A4 inducers (e.g. rifampicin).
CIMS Class
ATC Classification
P01BC02 - mefloquine ; Belongs to the class of methanolquinoline antimalarials.
Disclaimer: This information is independently developed by CIMS based on mefloquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in